✦ LIBER ✦

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib

✍ Scribed by Monica R. Maiello; Amelia D’Alessio; Antonella De Luca; Adele Carotenuto; Anna Maria Rachiglio; Maria Napolitano; Letizia Cito; Antonella Guzzo; Nicola Normanno

Book ID: 106377236
Publisher: Springer US
Year: 2006
Tongue: English
Weight: 290 KB
Volume: 102
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-006-9340-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Breast cancer cells with acquired resist

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

✍ Nicola Normanno; Manuela Campiglio; Monica R. Maiello; Antonella De Luca; Mario 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 408 KB

The MEK/MAPK pathway is involved in the

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

✍ Nicola Normanno; Antonella De Luca; Monica R. Maiello; Manuela Campiglio; Maria 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

## Abstract We investigated the role of the MEK/MAPK pathway in the sensitivity/resistance of breast carcinoma cells to the EGFR tyrosine kinase inhibitor gefitinib (IRESSA). We assessed the effects of gefitinib on the growth of three breast cancer cell lines that showed high (SK‐Br‐3; IC~50~ 4 µM)

Combined inhibition of IGFR enhances the

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors

✍ Yun Jung Choi; Jin Kyung Rho; Byung-suk Jeon; Su Jin Choi; Su Cheol Park; Seung 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 544 KB

ZD1839 (Iressa), a novel epidermal growt

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

✍ Neil G. Anderson; Tawhid Ahmad; Kai Chan; Richard Dobson; Nigel J. Bundred 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 192 KB 👁 1 views

Overexpression of the growth factor receptors EGFR and erbB2 occurs frequently in several human cancers and is associated with aggressive tumour behaviour and poor patient prognosis. We have investigated the effects of ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, on the growth, in vitro

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant

Additive antitumor effects of the epider

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro

✍ Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Danilo Millimaggi; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 618 KB

## Abstract Progression from an androgen‐dependent to an androgen‐independent state often occurs in patients with prostate cancer (PCa) who undergo hormonal therapy. We have investigated whether inhibition of the epidermal growth factor receptor (EGFR) signaling pathway affects the antitumor effect